A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …

Background There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits
several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and …

Background: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has
been a main priority of the field for decades. Dissatisfaction with existing measures has led …

Objective To investigate the effects of siponimod on cognitive processing speed in patients
with secondary progressive (SP) multiple sclerosis (MS), by means of a predefined …

Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability
independent of relapses and can occur with disease onset (primary progressive) or can be …

Background: Cognitive dysfunction is common in multiple sclerosis (MS) patients and has
important consequences for daily activities, yet, unlike motor function, is not routinely …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with substantial
heterogeneity in its clinical presentation. This makes diagnosis and effective treatment …

Purpose To investigate, by using resting-state (RS) functional magnetic resonance (MR)
imaging, thalamocortical functional connectivity (FC) and its correlations with cognitive …

Precise measurement of neurological and neuropsychological impairment and disability in
multiple sclerosis is challenging. We report a new test, the Multiple Sclerosis Performance …